Stockholm, Sweden: Scientists have found that some people being treated with selective serotonin reuptake inhibitors (SSRIs) have a greater tendency to commit violent crime. In addition, this effect seems to continue for up to 12 weeks after stopping SSRI treatment. This work is published in the peer-reviewed journal European Neuropsychopharmacology*, alongside a linked comment. The authors of both the paper and the comment note that the work indicates an association (rather than cause and effect) and urge caution in how the findings are interpreted.
A new report from the Institute for Scientific Information on Coffee (ISIC), entitled 'Coffee and its effect on digestion' reviews the latest research into coffee's effect on digestion, and indicates a potential protective effect against gallstones and gallstone disease,1,2,3 and pancreatitis4,5. The report also highlights other beneficial effects that coffee consumption may have on the process of digestion6-11, including supporting gut microflora17-19 and promoting gut motility12,13-16.
Philadelphia, May 29, 2020 - In a report in The Journal of Molecular Diagnostics, published by Elsevier, researchers describe a rapid, accurate novel assay for nondeletional alpha-thalassemia genotyping based on one-step nested asymmetric PCR melting curve analysis, which may enhance prenatal diagnosis, newborn screening, and large-scale population screening.
WASHINGTON - A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.
Mucus is the first line of defence against bad bacteria in our gut. But could it also be part of our defence against diseases of the brain?
Bacterial imbalance in the gut is linked with Alzheimer's disease, autism and other brain disorders, yet the exact causes are unclear.
Now a new research review of 113 neurological, gut and microbiology studies led by RMIT University suggests a common thread - changes in gut mucus.
An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles from Queen Mary University of London and Barts Cancer Centre, UK.
This is the first time an immune therapy has resulted in a survival advantage in this setting in bladder cancer, and will potentially benefit thousands of patients each year.
Wearing face masks at home might help ward off COVID-19 spread among family members
79% effective at curbing transmission--but only before symptoms emerge
Wearing face masks at home might help ward off the spread of COVID-19 infection among family members living in the same household, but only before symptoms develop, suggests a study of Chinese families in Beijing, accepted for publication in BMJ Global Health.
People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet, also revealed cancer-specific factors associated with increased mortality.
A Mount Sinai research team has identified one of the mechanisms that establish the skin as a protective barrier, a breakthrough that is critical to understanding and treating common skin conditions including eczema and psoriasis, according to a study published Thursday, May 28, in the scientific journal Genes & Development.
The first study of COVID-19 to specifically analyse the effect of the disease in hospitalised patients with diabetes has found that one in ten patients dies within 7 days of hospital admission, and one in five is intubated and mechanically ventilated by this point. The research is published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]), by Professor Bertrand Cariou and Professor Samy Hadjadj, diabetologists at l'institut du thorax, University Hospital Nantes, INSERM, CNRS, and University of Nantes, France, and colleagues.
Up to now, women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face an unanswered question about whether surgery and radiation to the tumor in the breast (local therapy) will prolong survival compared to the traditional treatment of systemic treatment alone. Data from the long-awaited E2108 randomized phase three trial show that the survival experience of the two treatments was the same; local therapy did not improve overall survival.
The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care--bortezomib, lenalidomide, and dexamethasone (VRd). Data from a planned interim analysis for efficacy and toxicity for the ENDURANCE (E1A11) randomized phase three trial will be presented in the plenary session of the American Society of Clinical Oncology (ASCO) annual meeting to occur virtually from May 29-31 (Abstract LBA3).
If physical distancing measures in Ontario are relaxed too much or too quickly, the province could see hospitals overwhelmed with COVID-19 patients as well as exponential growth in deaths, concludes new research involving a University of Guelph infectious disease modeller.
The findings, contained in a research letter published in Annals of Internal Medicine, suggest that if Ontarians increase their contacts to normal levels in the coming weeks, the virus will quickly spread and result in cases exceeding hospital ICU (intensive care unit) capacity.
For most people who die of cancer, the spread of the initial tumor is to blame. "Metastasis is what kills most cancer patients," says Serge Fuchs, a professor in Penn's School of Veterinary Medicine. "Yet there are not many, if any, drugs that specifically target metastatic processes."
A cancer therapy may shrink the tumor of a patient, and the patient may feel better. But unseen on a CT scan or MR image, some of the cells are undergoing ominous changes. Fueled by new genetic changes due to cancer therapy itself, these rogue cells are becoming very large with twice or quadruple the number of chromosomes found in healthy cells. Some of the cells may grow to eight, 16 or even 32 times the correct number. Quickly, they will become aggressive and resistant to treatment. They will eventually cause cancer recurrence.